DBVT · Insider Trading
DBV Technologies S.A. American Depositary Shares
Every open-market purchase and sale reported by DBVT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | Pharis Mohideen | Chief Medical Officer | Sell | −464 | −$1.25K |
| 2026-02-02 | Pharis Mohideen | Chief Medical Officer | Sell | −534 | −$2.60K |
| 2026-01-14 | 667, L.P. | Director | M | — | — |
| 2025-12-19 | SA Bpifrance | — | Sell | −16,845,465 | −$77.42M |
| 2025-11-25 | Pharis Mohideen | Chief Medical Officer | MIXED | +35,880 | −$23.21K |
| 2025-11-24 | Virginie Boucinha | Chief Financial Officer | A | +32,000 | — |
| 2025-11-24 | Daniel Tasse | CHIEF EXECUTIVE OFFICER | A | +964,000 deriv. | — |
| 2025-11-24 | Kevin Michael Trapp | Chief Commercial Officer | A | +55,000 | — |
| 2025-07-31 | Pharis Mohideen | Chief Medical Officer | Sell | −464 | −$1.03K |
| 2025-05-27 | Pharis Mohideen | Chief Medical Officer | Sell | −397 | −$730 |
| 2025-03-31 | Felix Baker | Director | A | +327,658,752 deriv. | — |
| 2025-01-31 | Pharis Mohideen | Chief Medical Officer | Sell | −600 | −$510 |
| 2024-12-05 | Daniel Tasse | CHIEF EXECUTIVE OFFICER | A | +813,200 deriv. | — |
| 2024-11-27 | Pharis Mohideen | Chief Medical Officer | Sell | −907 | −$503 |
| 2024-11-25 | Pharis Mohideen | Chief Medical Officer | MIXED | +32,650 | −$1.27K |
| 2024-11-25 | Virginie Boucinha | Chief Financial Officer | A | +19,000 | — |
| 2024-07-31 | Pharis Mohideen | Chief Medical Officer | Sell | −1,785 | −$1.75K |
| 2024-05-29 | Pharis Mohideen | Chief Medical Officer | Sell | −1,042 | −$1.42K |
| 2024-03-11 | Daniel Tasse | CHIEF EXECUTIVE OFFICER | Buy | +17,094 | +$14.19K |
| 2024-02-08 | Adora Ndu | Director | Buy | +1,825 | +$1.62K |
| 2023-12-19 | Pharis Mohideen | Chief Medical Officer | Sell | −2,245 | −$3.91K |
| 2023-11-22 | Daniel Tasse | Chief Executive Officer | A | +806,672 deriv. | — |
| 2023-11-22 | Virginie Boucinha | Chief Financial Officer | A | +19,000 | — |
| 2023-11-22 | Pharis Mohideen | Chief Medical Officer | A | +35,000 | — |
| 2023-08-28 | Timothy E Morris | Director | Buy | +12,000 | +$18.24K |
| 2023-08-14 | Daniel Tasse | Chief Executive Officer | A | +764,386 deriv. | — |
| 2023-08-14 | Sebastien Robitaille | Chief Financial Officer | A | +8,000 | — |
| 2023-08-14 | Pharis Mohideen | Chief Medical Officer | MIXED | +25,239 | −$6.82K |
| 2023-08-03 | Daniel B Soland | Director | Buy | +15,000 | +$24.30K |
| 2022-06-13 | Baker Brothers Life Sciences LP | Director | A | +71,250,000 | — |
| 2021-11-24 | Daniel Tasse | Chief Executive Officer | A | +274,000 deriv. | — |
| 2021-11-24 | Sebastien Robitaille | Chief Financial Officer | A | +5,000 | — |
| 2021-11-24 | Pharis Mohideen | Chief Medical Officer | A | +8,700 | — |
| 2021-06-11 | Daniel B Soland | Director | Buy | +6,837 deriv. | — |
| 2021-06-11 | Michel De Rosen | Director | Buy | +6,837 deriv. | — |
| 2021-06-11 | Adora Ndu | Director | Buy | +6,837 deriv. | — |
| 2021-06-11 | Madduri Ravin Rao | Director | Buy | +6,837 deriv. | — |
| 2021-06-11 | Timothy E Morris | Director | Buy | +6,837 deriv. | — |
| 2021-06-11 | Viviane Monges | Director | Buy | +5,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| SA Bpifrance | — | 226,133 | $2.26M |
| Pharis Mohideen | Chief Medical Officer | 144,531 | $1.44M |
| Virginie Boucinha | Chief Financial Officer | 70,000 | $698.60K |
| Kevin Michael Trapp | Chief Commercial Officer | 55,000 | $548.90K |
| Daniel Tasse | CHIEF EXECUTIVE OFFICER | 1,709 | $17.06K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DBVT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.